# A Multi-Center, Double-Masked, Randomized, Vehicle-Controlled, Parallel-Group Clinical Trial Evaluating the Safety of Reproxalap Ophthalmic Solution in Subjects With Dry Eye Disease

> **NCT04735393** · PHASE3 · COMPLETED · sponsor: **Aldeyra Therapeutics, Inc.** · enrollment: 757 (actual)

## Conditions studied

- Dry Eye Disease

## Interventions

- **DRUG:** Reproxalap Ophthalmic Solution (0.25%)
- **DRUG:** Placebo Comparator
- **DRUG:** Reproxalap Ophthalmic Solution (0.25%)
- **DRUG:** Placebo Comparator

## Key facts

- **NCT ID:** NCT04735393
- **Lead sponsor:** Aldeyra Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-01-26
- **Primary completion:** 2022-10-11
- **Final completion:** 2022-10-11
- **Target enrollment:** 757 (ACTUAL)
- **Last updated:** 2025-11-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04735393

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04735393, "A Multi-Center, Double-Masked, Randomized, Vehicle-Controlled, Parallel-Group Clinical Trial Evaluating the Safety of Reproxalap Ophthalmic Solution in Subjects With Dry Eye Disease". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04735393. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*